Results 111 to 120 of about 7,486 (163)

Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report. [PDF]

Cureus
Lo T, Hassan L, Wilson S, Seri R, Hang S.   +4 more
europepmc   +1 more source

Predictors of B-cell repopulation in people with multiple sclerosis treated with ocrelizumab: insights from two large cohorts. [PDF]

J Neurol Neurosurg Psychiatry
Hogenboom L, McLean A, Schoof L, Taylor L, Strijbis EM, Killestein J, van Kempen ZLE, Kalincik T, Roos I.   +8 more
europepmc   +1 more source

Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis. [PDF]

Neurology
Schoof L, Heijnen R, Hogenboom L, Van Kempen ZLE, de Jong BA, Van Oosten BW, Killestein J, Barkhof F, Strijbis EM.   +8 more
europepmc   +1 more source

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

, 2019
OBJECTIVE: To assess the onset of ocrelizumab efficacy on brain MRI measures of disease activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled phase III studies in relapsing multiple sclerosis (RMS)
Sauter, A, Bar-Or, A, Han, J, Li, DKB, Barkhof, F, Julian, L, Hartung, H-P, Hauser, SL, Kappos, L, Koendgen, H, Belachew, S, Wolinsky, JS, Napieralski, J   +12 more
core  

Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model. [PDF]

Pharmacoecon Open
Porta C, Di Procolo P, Marrazzo G, Belfiore M, Palladino R, Brescia Morra V, Moccia M.   +6 more
europepmc   +1 more source

Unusual Sequential Development of Multiple Sclerosis, Thymoma, Myasthenia, and Lymphoma in the Same Patient. [PDF]

Case Rep Med
Finsterer J.
europepmc   +1 more source

Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis. [PDF]

Clin Pharmacokinet
Serkland TT, Oma AF, Hallin EI, Øverås MH, Nygaard GO, Myhr KM, Torkildsen Ø, Röblitz S, Skrede S.   +8 more
europepmc   +1 more source

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab. [PDF]

Eur J Neurol
Hogenboom L, Schoof LG, Gelissen LMY, Mostert J, van Rooij L, Hoitsma E, van Munster CEP, van Eijk J, Kalkers NF, Adriani KS, Vennegoor A, Arts IMP, Mensing L, Eurelings M, de Gans K, Gerlach O, Hoogervorst ELJ, Kloosterziel ME, Kragt JJ, Portier RP, Smets I, van Geel BM, Nielsen J, Roosendaal CM, Piet JR, Zeinstra E, Groeneveld ON, van Oosten BW, de Jong BA, Uitdehaag BMJ, Strijbis EMM, Lissenberg-Witte BI, Killestein J, van Kempen ZLE.   +33 more
europepmc   +1 more source

Errate: Nasal Mucociliary Clearance and Its Relationship With Disease Severity in Patients With Multiple Sclerosis. [PDF]

Med Sci Monit
Baydar C, Yalınkılıç A, Çetin YS.
europepmc   +1 more source

Finite depletion, sustained control: can impulse therapy prevent rebound activity in multiple sclerosis? [PDF]

J Neurol Neurosurg Psychiatry
Pawlitzki M, Masanneck L, Scalfari A, Giovannoni G.   +3 more
europepmc   +1 more source